• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    12/18/23 12:32:13 PM ET
    $AHG
    $BMRA
    $CARA
    $CKPT
    Real Estate
    Real Estate
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $AHG alert in real time by email

    Gainers

    • Invivyd (NASDAQ:IVVD) stock moved upwards by 157.7% to $4.2 during Monday's regular session. The market value of their outstanding shares is at $462.4 million.
    • Panbela Therapeutics (NASDAQ:PBLA) stock rose 123.14% to $1.02. The market value of their outstanding shares is at $5.2 million.
    • Biomerica (NASDAQ:BMRA) shares increased by 65.64% to $1.64. The market value of their outstanding shares is at $27.5 million.
    • ZimVie (NASDAQ:ZIMV) shares increased by 42.24% to $15.96. The company's market cap stands at $423.5 million.
    • Akso Health Group (NASDAQ:AHG) stock moved upwards by 37.58% to $0.83. The company's market cap stands at $18.8 million.
    • SenesTech (NASDAQ:SNES) stock moved upwards by 25.69% to $0.74.

    Losers

    • Cara Therapeutics (NASDAQ:CARA) stock fell 46.7% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $35.7 million.
    • Checkpoint Therapeutics (NASDAQ:CKPT) stock decreased by 46.69% to $1.77. The market value of their outstanding shares is at $41.6 million.
    • Minerva Surgical (NASDAQ:UTRS) stock fell 36.53% to $1.79. The market value of their outstanding shares is at $15.8 million.
    • Structure Therapeutics (NASDAQ:GPCR) stock fell 35.52% to $38.15. The company's market cap stands at $1.7 billion.
    • Lantheus Holdings (NASDAQ:LNTH) shares declined by 25.54% to $56.62. The market value of their outstanding shares is at $3.8 billion.
    • Gossamer Bio (NASDAQ:GOSS) stock decreased by 25.5% to $0.76. The market value of their outstanding shares is at $171.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $BMRA
    $CARA
    $CKPT

    CompanyDatePrice TargetRatingAnalyst
    Lantheus Holdings Inc.
    $LNTH
    2/26/2026Mkt Perform → Outperform
    William Blair
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Neutral
    Wedbush
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$0.30Overweight → Equal Weight
    Barclays
    Gossamer Bio Inc.
    $GOSS
    2/24/2026$1.00Outperform → Market Perform
    Leerink Partners
    Gossamer Bio Inc.
    $GOSS
    1/28/2026$9.00Overweight
    Barclays
    Invivyd Inc.
    $IVVD
    12/22/2025$10.00Buy
    BTIG Research
    Lantheus Holdings Inc.
    $LNTH
    12/12/2025$80.00Hold → Buy
    Truist
    Invivyd Inc.
    $IVVD
    11/25/2025Buy → Hold
    D. Boral Capital
    More analyst ratings

    $AHG
    $BMRA
    $CARA
    $CKPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BMRA
    $CARA
    $CKPT
    SEC Filings

    View All

    SEC Form PRE 14A filed by Lantheus Holdings Inc.

    PRE 14A - Lantheus Holdings, Inc. (0001521036) (Filer)

    3/10/26 5:18:10 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-K filed by Invivyd Inc.

    10-K - Invivyd, Inc. (0001832038) (Filer)

    3/5/26 7:20:57 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

    8-K - Invivyd, Inc. (0001832038) (Filer)

    3/5/26 7:11:42 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHG
    $BMRA
    $CARA
    $CKPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/6/26 5:40:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $AHG
    $BMRA
    $CARA
    $CKPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Niedzwiecki Daniel was granted 36,692 shares and covered exercise/tax liability with 1,283 shares, increasing direct ownership by 42% to 119,376 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    3/9/26 5:06:05 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Officer Dinkelborg Ludger was granted 20,966 shares, increasing direct ownership by 142% to 35,731 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    3/9/26 5:05:49 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CFO and Treasurer Marshall Robert J. Jr. was granted 38,002 shares and covered exercise/tax liability with 1,182 shares, increasing direct ownership by 43% to 122,792 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    3/9/26 5:05:33 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AHG
    $BMRA
    $CARA
    $CKPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lantheus Holdings upgraded by William Blair

    William Blair upgraded Lantheus Holdings from Mkt Perform to Outperform

    2/26/26 12:20:43 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Gossamer Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00

    2/24/26 8:01:18 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gossamer Bio downgraded by Barclays with a new price target

    Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $0.30

    2/24/26 7:42:57 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BMRA
    $CARA
    $CKPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

    New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger batches and greater patient availability PYLARIFY TruVu™ is expected to launch in 4Q 2026, with a phased geographic rollout to support a seamless customer transition BEDFORD, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has approved PYLARIFY TruVu (pifl

    3/6/26 4:01:00 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

    UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great BritainActive Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics. IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced that it has receiv

    3/5/26 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AHG
    $BMRA
    $CARA
    $CKPT
    Financials

    Live finance-specific insights

    View All

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

    Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025DECLARATION trial on track with full enrollment achievedDECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC re

    3/5/26 7:03:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

    NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15 minutes prior to the start time. A recording of the webcast will be available on the company's investor rel

    3/2/26 4:10:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHG
    $BMRA
    $CARA
    $CKPT
    Leadership Updates

    Live Leadership Updates

    View All

    Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

    Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital, Dr. Mina strengthens Invivyd's medical leadership Dr. Mina's research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other diseases, and will be a significant asset to Invivyd and the advancement of its pipelineWith more than 100 scientific publications and 10,000 citations, as well as hundreds of popular press interviews and op-eds, Dr. Mina is an expert in conducting research and conveying its meaning and impact to healthc

    3/5/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

    NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (NASDAQ:IVVD) is hosting the previously announced live webcast to present an overview of the company's REVOLUTION clinical program, Invivyd's development program for VYD2311, a vaccine-alternative monoclonal antibody candidate for the prevention of COVID. The session will feature key members of the Invivyd team. WHEN: Thursday, October 30, 2025, at 8:30 a.m. ET WHERE: Listeners are advised to join the webcast via the following link 15 minutes prior to the start time. A replay of the webcast will be available via the investor relations section of the company's website approximately two hours after the conclusion of

    10/28/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHG
    $BMRA
    $CARA
    $CKPT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BMRA
    $CARA
    $CKPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

    SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

    12/12/24 4:39:09 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials